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Abstract20
Paediatrics and geriatrics both represent highly heterogenous populations and require
special consideration when developing appropriate dosage forms. This paper
discusses similarities, differences and considerations with respect to the development
of appropriate medicine formulations for paediatrics and geriatrics. Arguably the
most significant compliance challenge in older people is polypharmacy, whereas for25
children the largest barrier is taste. Pharmaceutical technology has progressed rapidly
and technologies including FDCs, multi-particulates and orodispersible dosage forms
provide unprecedented opportunities to develop novel and appropriate formulations
for both old and new drugs. However, it is important for the formulation scientists to
work closely with patients, carers and clinicians to develop such formulations for both30
the paediatric and geriatric population.
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2Paediatric and geriatric patients do not fall into the category of ‘standard patient’ due35
to altered pharmacokinetics, different acceptable dosage forms, formulation
composition and route of administration. In the paediatric population, there are
distinct physiological differences between neonates, infants, children and adolescents.
However, relating this information to adult data when determining an appropriate
dosing regimen is complicated (Bartelink et al., 2006). In neonates and infants,40
immaturity of enzymes, volume of distribution and clearance may result in differences
in pharmacokinetics. In older people, these differences cannot be defined by age
alone. Pharmacokinetics are strongly influenced by morbidity, co-morbidity, multiple
drug use or reduced organ function. The ICH Harmonised Tripartite Guideline:
Studies in Support of Special Populations: Geriatrics E7 highlights the need to45
conduct pharmacokinetic studies in healthy geriatric subjects or volunteers with the
disease to be treated by the drug of interest. It is not uncommon for clinical trials to
exclude older patients, for reasons such as concomitant conditions, polypharmacy or
frailty, yet this data is essential to maintain safety and optimise medication for the
older population (Ford, 2000; Mangoni and Jackson, 2004). If age-related differences50
are found that could be of medical importance, a larger, multiple-dose PK study may
be necessary to permit statistical comparisons between different patient cohorts at
steady state (International Conference on Harmonisation, 1993). Similarly, the
Paediatric Regulation was introduced in 2007 to ensure that medicines for use in
children are of high quality, ethically researched and appropriately authorised.55
In both paediatric and geriatric population groups, challenges exist in the development
of formulations that will offer a predictable and safe drug release in the patient, whilst
also being presented in an acceptable dosage form to ensure safety and compliance.
Manufacturing complexity and cost are also important considerations. From an60
industry perspective, the paediatric population represent a small market, with many
illnesses short term. Adopting a patient centric approach for such a small target group
can be difficult financially, requiring significant labour and resources. The geriatric
population, on the other hand, are a wider group with a broad range of therapeutic,
hence pharmaceutical, needs. By considering the similarities between the paediatric65
and geriatric population, labour and resource costs may be minimised whilst
maintaining this patient focus. This paper outlines some of the paediatric and geriatric
formulation needs from a patient centric perspective, with a focus on novel
3oral systems such as fixed-dose combinations, multi-particulates and orodispersible
dosage forms. Patient centric formulation development refers to considering the70
end user from the beginning of the formulation process and right through the
development to an end product.
Excipient and other formulation issues
Excipients of medications that may be acceptable in adult formulations may not be75
suitable for special populations such as paediatrics and geriatrics. For example, high
sodium intake disturbs electrolyte balance, causing water retention and increasing the
risk of cardiovascular conditions including stroke, hypertension and heart failure,
particularly in older adults (George et al., 2013). Despite this, a recent review of
cardiovascular formulations listed in the British National Formulary (BNF) found80
instances where effervescent, dispersible and soluble tablets prescribed for
cardiovascular disorders contained sodium levels higher than the recommended daily
intake of sodium in adults (2.4g or 104mmol) (Hanning et al., 2015; Joint Formulary
Committee, 2013). In addition, only 40% of medicines listed in the BNF for
cardiovascular disorders specified dose recommendations that could be adjusted for85
older patients, taking into consideration factors such as comorbidity, polypharmacy
and vulnerability to adverse effects (Hanning et al., 2015).
For children the situation is even more critical, as the vast majority of medicines
prescribed for children with cardiovascular problems are unlicensed and often90
manipulated at the point of administration or only available as extemporaneous
formulations (Standing and Tuleu, 2005). Implications of this include dosing
accuracy, unknown bioavailability of extemporaneously prepared formulations, use of
excipients that may be toxic and a lack of access to modified release preparations for
children. Although the introduction of the European Union regulation on medicinal95
products for paediatric use in 2007 has endeavoured to improve rational, evidence-
based prescribing and age-appropriate formulations for children, a significant number
of products still lack paediatric information (Breitkreutz; Frattarelli et al., 2014; Sachs
et al., 2012).100
Oral drug delivery is the most popular route of medicine administration. Advantages
include ease of ingestion, avoidance of administration discomfort/pain, low
4manufacture cost, versatility and expected better patient compliance (Sastry et al.,
2000). Many individuals find it difficult to swallow tablets and hard gelatin capsules
and this difficulty is especially prevalent in paediatric and geriatric patients (Lindgren105
and Janzon, 1991; Patel et al., 2015). Co-administration with food is often
recommended to ease ingestion of medication, although this practice might have an
impact on the oral bioavailability of the drug. Depending on the active moiety and the
type of food this can result in an increased or decreased exposure (Martinez and
Amidon, 2002). Therefore, recommendations need to be made in a case-by-case basis.110
Critically, food preferences may vary between paediatric and geriatric individuals, so
a variety of food types need to be considered. Not only food, but also oral vehicles
(syrups and gels) and thickening agents (which can be added to a drink to increase its
consistency) have been investigated and proposed. These administration aids could be
supplied along with the drug product, could be commercially available as a separate115
product, or could be extemporaneously prepared in community pharmacies as
required (Kluk and Sznitowska, 2014). Caution must be taken with recommending
these products until sufficient scientific evidence with regards to the safety of this
practice is generated. In fact, preliminary data suggest that thickening agents could
hinder release of drugs from crushed tablets (Manrique et al., 2014). Further research120
in this topic is required to enable safe administration of medication with food and
thickening agents.
Fixed-dose combinations
Fixed-dose combinations (FDCs) are a way of administering multiple medications in125
a single dosage form. Their primary advantage is to reduce complexity of therapy and
improve medication compliance by reducing pill burden in patients with co-
morbidities. Therefore, FDCs address two key determinants of poor medication
compliance – polypharmacy and the complexity of treatment regimen. FDCs have
been shown to decrease the risk of medication non-compliance in patients with130
chronic conditions (Bangalore et al., 2007). In addition, the combination of drugs with
different mechanism of action can achieve greater efficacy (synergistic effect) with a
lower occurrence of adverse events compared to increasing the dose of the
monotherapy (Garber et al., 2002; Panaccione et al., 2014). Other advantages include
the simplification of drug handling and lower packing and shipping costs. FDCs are135
primarily advantageous for geriatric patients with polypharmacy, however, can also
5be helpful for paediatrics in conditions requiring combined medication, such as
tuberculosis and HIV. Although some commercial FDC preparations exist, such as
Rifater® and Rifanah® (Sanofi-Aventis) for the treatment of tuberculosis, these are not
licenced for use in children. However, these preparations could be considered in140
older children provided that the dose of each drug is appropriate given the weight of
the child (BMJ Group, 2011).
FDCs also have some potential limitations. FDCs restrict individual dose titration of
each active ingredient which, indeed, discourages adjustment of doses to the145
individual patient’s need (Blomberg et al., 2001; World Health Organisation, 2003).
This is of critical importance when the combined drugs exhibit different
pharmacokinetics and/or pharmacodynamics. Unless each active ingredient is
available as a separate drug product, FDCs encourage polypharmacy irrespective of
the appropriateness of drug combination for a particular patient (World Health150
Organisation, 2003). The incorporation of various drugs in single dosage forms pose
unprecedented technical challenges which arise from incompatibilities of the
combined drugs (Singh et al., 2001). Furthermore, the final dosage form may become
significantly larger, obstructing oral administration (Desai et al., 2013). This is of
particular importance if an individual suffers from dysphagia or struggles to swallow155
tablets, which are common features in the geriatric and paediatric population. Some of
these challenges might be overcome via the preparation of multi-particulate
formulations or oral fast dissolving dosage forms.
Multi-particulate formulations160
Compared to single dose units, which usually take the form of a tablet, multi-
particulate formulations are smaller, multiple unit systems of mini-tablets or pellets
that are either filled into capsules or compressed into tablets that disintegrate into the
original pellet size on administration (Newton, 2010). In some cases, the dose may be
adapted to meet patient requirements, for example the administration of a quantity of165
pellets based on body weight. The utilisation of specialised counting and dosing
devices may be necessary in these instances (Wening and Breitkreutz, 2011) and new
research is on-going in this area.
6Commercial examples of multiparticulate formulations include Depakote® capsules170
(divalproex sodium) and Creon® capsules (pankrelipase), whereby the capsules can be
swallowed whole, or if swallowing is an issue the capsule contents may be sprinkled
onto soft food. As discussed previously, the type of food that is used as the vehicle in
these instances is important, although often little instruction is given.175
Multi-particulate formulations are a good choice for the development of FDC
products since individual dosage units containing different entities can be combined
in the final dosage form (e.g. filled into capsules). This approach clearly presents
fewer limitations from a pharmaceutical development perspective than the
combination of drugs in the same dosage unit, particularly in the case of drugs with180
physical or chemical incompatibilities (Desai et al., 2013). Thus, multi-particulate
formulations offer great design flexibility by combining particles with different drugs
and/or with different release profiles. This type of formulation is also a great
candidate for the preparation of controlled release products with minimal risk of dose
dumping. Due to their reduced size, multi-particulates are expected to exhibit a185
shorter and more reproducible gastric emptying than single-unit dosage forms, which
is desirable in the design of controlled release products. However, evidence in this
area is limited in the young and the old, as studies have focused in the adult
population only (Newton, 2010; Varum et al., 2010). Paediatric and, in particular,
geriatric patients with chronic conditions may benefit from controlled release products190
to reduce the frequency of administration and ultimately the pill burden.
Many barriers and unknowns arise at the point of administration of pellets and mini-
tablets. The maximum number of dosage units that can be administered in a single
dose has not yet been investigated for any targeted patient group. This is important as195
it defines the maximum dose that can be delivered, which could hinder the preparation
of FDC if the dose required exceeds the maximum delivery dose.
In spite of the acclaimed advantages of this type of formulation, the number of
products in the market is still limited. The development of multi-particulate systems200
may require advanced pharmaceutical technology, multiple step processes and
diligent control of processing variables. This can entail a time-consuming and costly
production with respect to conventional solid dosage forms (Roy and Shahiwala,
72009), although in practice multi-particulates could be manufactured in the same way
as conventional tablets but down to 1mm diameter (Tissen et al., 2011), using an205
established and well-controlled process. It is important that the combination of multi-
particulate technology with the selected drug substance and packaging system is
prosperous to achieve patient acceptance and smooth the path for other medicines to
take the form of multi-particulate products. Oral fast-dissolving dosage forms are a
more established platform that have already come a long way, with many patients210
already benefiting from this novel approach to drug delivery in various therapeutics
areas.
Orodispersible dosage forms
Orodispersible dosage forms are those that disintegrate or dissolve rapidly in the oral215
cavity, resulting in a solution or suspension without the need for water. Examples of
commercially manufactured orodispersible dosage forms are highlighted in Table 1.
In terms of specific use for paediatric and geriatric population groups, their primary
advantage is their ability to be administered to those with difficulties swallowing solid
dosage forms (Sastry et al., 2000). However, disadvantages include limited drug220
loading and the requirement for taste masking.
Orodispersible tablets (ODTs) and oral lyophilisates dominate the market of oral fast-
dissolving dosage forms (Slavkova and Breitkreutz, 2015). Similar in appearance to
conventional tablets, these solid formulations disintegrate quickly in the oral cavity225
thanks to a rational selection of excipients (e.g. superdisintegrants) and/or
manufacturing processes which confer higher tablet porosity (Al-khattawi and
Mohammed, 2014; Badgujar and Mundada, 2011). Orodispersible films (ODFs) are
thin strips of film that undergo rapid disintegration in the oral cavity when placed on
the tongue (Hoffmann and Breitenbach, 2011). Alternative fast-dissolving dosage230
forms are being introduced including orodispersible granules and orally disintegrating
mini-tablets (Krause et al., 2009; Stoltenberg and Breitkreutz, 2011).
Table 1 Examples of marketed orodispersible tablets, oral lyophilisates and
orodispersible films. Adapted from Slavkova and Breitkreutz (2015).235
Dosage form Examples of marketed products
8Orodispersible tablets Prevacid solutab (lansoprazole), Allegra
(fexofenadine hydrochloride), Orapred ODT
(prednisolone), Parcopa (levodopa/carbidopa),
Zomig-ZMT (zolmitriptan)
Oral lyophilisates Zofran Zydis (ondansetron), Imodium akut lingual
(loperamide), Zyprexa Velotab (olanzapine),
Clarinex Reditabs (loratadine), Zelapar (selegiline),
Maxalt-lingua (Rizatriptan benzoate)
Orodispersible films Setofilm (ondansetron), Zuplenz (ondansetron),
Risperidone Hexal SF (risperidone), Donezepil-HCl
Hexal SF (Donezepil hydrochloride)
A fundamental gap in the development of fast-dissolving dosage forms is the lack of
officially recognised characterisation methods. According to the European
Pharmacopoeia 7.4, orodispersible preparations should be produced in a way that they
possess suitable mechanical strength to withstand handling without being damaged,240
but the only specific test mentioned is dissolution. Despite this, there is no clear
indication of how long an orodispersible preparation should take to disintegrate and
there is no clearly defined endpoint for disintegration in the European Pharmacopoeia.
This is particularly important as the disintegration time is a vital property that affects
drug administration and drug release (Pein et al., 2014). Compendial disintegration245
testing has shown very poor correlation with in vivo disintegration time in the mouth,
while novel testing techniques can attain much better correlation (Brniak et al., 2012;
Hoashi et al., 2013; Szakonyi and Zelkó, 2013). In addition to fast disintegration other
ideal properties include flexibility (in the case of films), physical stability, good
handling and suitable mechanical strength (Visser et al., 2015).250
Palatability and in particular taste are key attributes of oral fast-dissolving dosage
forms as the formulation is intended to disintegrate in the oral cavity. The utilisation
of taste-masking technologies in combination with oral fast-dissolving dosage forms
is often required (Douroumis, 2011). Several techniques might be considered, either255
alone or in combination, to attain taste masking. The addition of sweeteners and
flavouring agents are often the first approach investigated since special
9manufacturing technologies or equipment are not required and the pharmacokinetic
properties of the drug product are not likely to be affected (Walsh et al., 2014). The
use of complexation (e.g. ion exchange resins) or coating (e.g. sugar, polymeric or260
lipidic coating) to apply a molecular or physical barrier between drug and palate is
considered to be more effective than the sole addition of sweeteners and flavours;
however, this approach could have an impact on the bioavailability of the product
and is also more technically challenging (Walsh et al., 2014). Selection of the most
appropriate taste-masking technique needs to be rationalised based on the265
physicochemical and organoleptic properties of the drug.
The evaluation of taste and overall palatability is becoming common practice. Taste
assessment can be performed by means of dissolution testing in bio-relevant
conditions (Tan et al., 2013), in vitro techniques such as electronic tongues (Preis et270
al., 2012), in vivo animal models (Noorjahan et al., 2014), or with a panel of human
volunteers (Pein et al., 2014). Studies using human taste panels are typically
conducted in adults, which can be problematic when the target population is
paediatrics and geriatrics, who have different taste sensations (Krause and
Breitkreutz, 2008). Appropriate palatability is particularly important in the case of275
medicines for children. The current European guidelines urge the assurance of
appropriate palatability in paediatric products (European Medicines Agency, 2013).
The future direction of pharmaceutical development of medicines for paediatric
and geriatric use280
Both geriatric and paediatric patients, particularly of extreme age, sometimes find it
difficult to swallow; therefore, flexible dosing and appropriate strengths of
formulations are needed. In terms of difference in disease incidence and distribution
in neurological disorders, pharmaceutical research in older patients should focus on
neurodegenerative diseases and disorder due to neuro-insult such as Parkinson’s285
disease, Alzheimer’s, stroke and epilepsy, all these illnesses still require appropriate
formulation to assist the carers to administer and patient to swallow. Similarly,
neurodevelopmental disorders in children also create significant challenges. Illnesses
such as Autism Spectrum Disorder, cerebral palsy and epilepsy all require careful
formulation research to develop appropriate medicines that assist the ease of290
administration for the carers and also make it easy for the patient to swallow.
10
Another important clinical area for formulation research is palliative care for both
older people and children. As the population ages, there is clearly an increased need
for palliative care. Palliative care patients require medications to be administered295
within their homecare settings to allow them to stay in a familiar environment;
however, many medicines for fast symptom relief require injection. This route could
be potentially replaced by non-invasive dosage forms, such as orodispersible and
oromucosal formulations and current research is working towards addressing this.
The above-mentioned issues are also applied to paediatric palliative care, but with the300
added complexity due to the small dose requirement that the appropriate formulation
is very important to avoid accidental overdose.
The most appropriate dosage form and manufacturing technology need to be selected
considering the physicochemical properties of the drug, but also the target population.305
Novel technologies including inkjet and 3D printing bring unparalleled opportunities
for the preparation of personalised medicines, either in industrial settings or in
hospitals and community pharmacies. Investment and development of infrastructure
are required for this to be feasible and adaptations of regulatory framework are
already underway to support this (Food and Drug Administration, 2013). In August310
2015, a 3D-printed drug became the first of its type to be approved by the FDA,
which reinforces promise for this direction. Spritam (levetiracetam), developed by
Aprecia Pharmaceuticals (Langhorne, Pennsylvania), uses the company’s ZipDose
Technology platform, which applies powder-liquid 3D printing to produce a porous
formulation that rapidly disintegrates with a small volume of liquid (Voelker, 2015).315
Pharmaceutical technology has progressed rapidly and many of the above-mentioned
technologies provide unprecedented opportunities to develop novel and appropriate
formulations for both old and new drugs. However, it is important for the formulation
scientists to work closely with patients, carers and clinicians to develop such320
formulations for both older people and children.
Conclusions
Paediatric and geriatric populations deviate from the standard patient with respect to
both pharmacokinetics and pharmacodynamics. These changes require dose325
11
adaptations and careful selection of excipients when developing a dosage form.
Although there is considerable overlap when it comes to ‘ideal’ formulations and
dosage forms for these two population groups, there are also key differences that
require consideration.. The development of novel drug delivery systems including
FDCs and multi-particulates may help to address some of these problems in both330
population groups. In addition, regulatory expectations are being established to help
facilitate the development of dosage forms that are suitable for paediatric and
geriatric populations. The release of further regulatory guidance documents and
academic research articles as well as success stories in the form of licensed patient
centric products will drive the future of paediatric and geriatric appropriate335
formulations.
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